Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 11

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI

İkili antitrombositer tedavi altında tirofibanın primer PCI yapılan STYMI hastalarındaki rolü

Pages
956–956
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

TÜRKER, Y. (2022). Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 11, 956–956. https://ajindex.com/articles/597296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Kaymaz C, Keleş N, Özdemir N, Tanboğa İH, Demircan HC, Can MM, et al. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. Anatol J Cardiol 2014 Dec 25. Epub ahead of print
  2. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of random-ized trials. Eur Heart J 2009; 30: 2705-13. [CrossRef] 3. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-17. [CrossRef] 4. Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter Cardiovasc Interv 2010; 75: 895-902. [CrossRef] 5. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al; Task Force on the management of ST-segment elevation acute myocar-dial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619. [CrossRef] 6. Mrdovic I, Savic L, Lasica R, Krljanac G, Asanin M, Brdar N, et al. Efficacy and safety of tirofiban-supported primary percutaneous coronary interven-tion in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. Eur Heart J Acute Cardiovasc Care 2014; 3: 56-66. [CrossRef] 7. Zhu J, Zhang T, Xie Q, Zhang J. Effects of upstream administration of tirofi-ban before percutaneous coronary intervention on spontaneous reperfu-sion and clinical outcomes in acute ST-segment elevation myocardial infarction. Angiology 2015; 66: 70-8. [CrossRef] 8. Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonper-cutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2: 917-24. [CrossRef]